TY - JOUR
T1 - Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy
AU - Jiang, Hong
AU - Hegde, Samarth
AU - DeNardo, David G.
N1 - Publisher Copyright:
© 2017, Springer-Verlag Berlin Heidelberg.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Tumor-associated fibrosis is characterized by unchecked pro-fibrotic and pro-inflammatory signaling. The components of fibrosis including significant numbers of cancer-associated fibroblasts, dense collagen deposition, and extracellular matrix stiffness, are well appreciated regulators of tumor progression but may also be critical regulators of immune surveillance. While this suggests that the efficacy of immunotherapy may be limited in highly fibrotic cancers like pancreas, it also suggests a therapeutic opportunity to target fibrosis in these tumor types to reawaken anti-tumor immunity. This review discusses the mechanisms by which fibrosis might subvert tumor immunity and how to overcome these mechanisms.
AB - Tumor-associated fibrosis is characterized by unchecked pro-fibrotic and pro-inflammatory signaling. The components of fibrosis including significant numbers of cancer-associated fibroblasts, dense collagen deposition, and extracellular matrix stiffness, are well appreciated regulators of tumor progression but may also be critical regulators of immune surveillance. While this suggests that the efficacy of immunotherapy may be limited in highly fibrotic cancers like pancreas, it also suggests a therapeutic opportunity to target fibrosis in these tumor types to reawaken anti-tumor immunity. This review discusses the mechanisms by which fibrosis might subvert tumor immunity and how to overcome these mechanisms.
KW - Extracellular matrix
KW - Fibrosis
KW - Pancreas cancer
KW - Regulatory myeloid suppressor cells
KW - Tumor immunity
KW - Tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85018335599&partnerID=8YFLogxK
U2 - 10.1007/s00262-017-2003-1
DO - 10.1007/s00262-017-2003-1
M3 - Review article
C2 - 28451791
AN - SCOPUS:85018335599
SN - 0340-7004
VL - 66
SP - 1037
EP - 1048
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
IS - 8
ER -